TCD’s leading compound, TCD-717, is a small molecule that embodies the Company’s approach of combining Personalized Medicine and Targeted Therapy. The patient population eligible for treatment will be identified by testing tumors for ChoKa over-expression while TCD-717, a precisely-targeted ChoKa inhibitor, causes the destruction of malignant cells but merely arrests temporarily the life cycle of normal cells.
TCD-717 is administered intravenously in order to enable the drug to circulate through the body and destroy not only the primary tumor but also cancer metastasis.
TCD-717 has demonstrated outstanding therapeutic index and a high safety profile in in-vivo and in-vitro studies. The drug is currently undergoing GLP pre-clinical studies designed to support phase I multi indication clinical study of TCD-717 as a treatment for lung, breast and colorectal.
The cumulative potential market of all three indications currently in plan for Phase I reaches over 800,000 new patients a year who are eligible for treatment. The U.S. accounts for 255,000 of those new patients with the rest of the major developed markets accounting for the additional 545,000.
However, TCD-717 has far greater potential. The drug has a very broad spectrum and it has already demonstrated its efficacy for treating cervix, epidermis, pancreas, lymphoma, gland, liver, ovary, bone and kidney tumors under in-vitro conditions.
The Phase I clinical study will be conducted according to FDA and EMEA guidelines and is scheduled to begin in mid 2010.